LEADER 01705oam  2200457   450 
001 9910702554703321
005 20141217114704.0
035   $a(CKB)5470000002428631
035   $a(OCoLC)887720599
035   $a(EXLCZ)995470000002428631
100   $a20140818d2014      ua             0
101 0 $aeng
135   $aurbn||||a||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aReforming the drug compounding regulatory framework $ehearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Thirteenth Congress, first session, July 16, 2013
210  1$aWashington :$cU.S. Government Printing Office,$d2014.
215   $a1 online resource (vi, 190 pages)
300   $aTitle from title screen (viewed on Aug. 18, 2014).
300   $aPaper version available for sale by the Superintendent of Documents, U.S. Government Printing Office.
300   $a"Serial No. 113-70."
320   $aIncludes bibliographical references.
517   $aReforming the drug compounding regulatory framework 
606   $aDrugs$xDosage forms$zUnited States
606   $aPharmaceutical industry$zUnited States
606   $aDrug adulteration$zUnited States$xPrevention
608   $aLegislative hearings.$2lcgft
615  0$aDrugs$xDosage forms
615  0$aPharmaceutical industry
615  0$aDrug adulteration$xPrevention.
801  0$bGPO
801  1$bGPO
801  2$bGPO
801  2$bCOO
801  2$bOCLCO
801  2$bGPO
906   $aBOOK
912   $a9910702554703321
996   $aReforming the drug compounding regulatory framework$93501961
997   $aUNINA